RhumbLine Advisers
BIOA

RhumbLine Advisers’s BioAge Labs BIOA Stock Holding History

RhumbLine Advisers’s Portfolio BIOA Stock Details BIOA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.08M Buy
43,904
+8,584
+24% +$155K ﹤0.01% 2272
2026
Q1 		$618K Buy
35,320
+5,793
+20% +$112K ﹤0.01% 2476
2025
Q4 		$391K Buy
29,527
+875
+3% +$7.76K ﹤0.01% 2816
2025
Q3 		$168K Sell
28,652
-1,484
-5% -$6.95K ﹤0.01% 3314
2025
Q2 		$124K Buy
30,136
+20,336
+208% +$81.9K ﹤0.01% 3453
2025
Q1 		$36.8K Buy
9,800
+5,942
+154% +$27.5K ﹤0.01% 3639
2024
Q4 		$22.3K Buy
+3,858
New +$66.5K ﹤0.01% 3792

Other funds holding BIOA

ACM
AH Capital Management Menlo Park, California $14.2B AUM 20.01% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

RhumbLine Advisers's BIOA Position: Q2 2026 in Review

RhumbLine Advisers increased its BioAge Labs (BIOA) stake by 24% in Q2 2026, buying an estimated $155K and bringing the position to 43,904 shares worth $1.08M. The position accounts for ﹤0.01% of the portfolio, ranked #2272.

RhumbLine Advisers first reported a position in BIOA in Q4 2024 and has held it in 7 quarters since. 151 funds tracked by Wall St. Rank hold BIOA as of Q2 2026.

  • RhumbLine Advisers held 43,904 shares of BioAge Labs worth $1.08M as of Q2 2026.
  • RhumbLine Advisers bought 8,584 BioAge Labs shares in Q2 2026, an estimated $155K.
  • BioAge Labs made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #2272 holding.
  • RhumbLine Advisers first reported a position in BioAge Labs in Q4 2024 and has held it in 7 quarters since.
  • 151 funds tracked by Wall St. Rank held BioAge Labs as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.